dexamethasone / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

92 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dexamethasone / Generic mfg.
NCT00049478: PS-341 in Treating Patients With Refractory or Progressive Multiple Myeloma

Active, not recruiting
3
US
bortezomib, dexamethasone
Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI)
Multiple Myeloma and Plasma Cell Neoplasm
 
 
2009-016871-32: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)

Ongoing
3
700
Europe
REVLIMID (LENALIDOMODE), REVLIMID (LENALIDOMIDE), VELCADE (BORTEZOMIB), REVLIMID (LENALIDOMIDE), VELCADE (BORTEZOMIB), REVLIMID (LENALIDOMIDE), VELCADE (BORTEZOMIB)
CHU de TOULOUSE, , PHRC National/Ministère de la Santé, Celgene International SARL, Janssen Pharmaceutica NV, Amgen
Myeloma, Multiple Myeloma
 
 
2009-013856-61: Randomisierte, offene, multizentrische Phase III Studie zum Vergleich von Lenalidomid/Dexamethason versus Lenalidomid/Dexamethason mit anschließender autologer Blutstammzelltransplantation und Lenalidomid Erhaltungstherapie für Patienten mit rezidiviertem Multiplen Myelom

Ongoing
3
282
Europe
autologous PBSC, CD34+ cells, Revlimid®, Revlimid®
University Hospital Heidelberg, Amgen, Celgene, Chugai, Hopp-Foundation
Multiple Myeloma (1.-3. Progression/Relapse)
 
 
2012-004873-14: Prevention of macular edema after cataract surgery Het voorkomen van netvlieszwelling na een staaroperatie

Ongoing
3
246
Europe
Bromfenac, Dexamethasone, Bevacizumab, Triamcinolone Acetonide, Yellox, Dexamethasone, Avastin, Triesence, Yellox, Dexamethasone, Avastin, Triesence
University Eye Clinic Maastricht, University Eye Clinic Maastricht UMC, ESCRS (European Society of Cataract & Refractive Surgeons), Bausch + Lomb, ESCRS (European Society of Cataract and Refractive Surgeons), Bausch & Lomb
Pseudophakic cystoid macular edema (PCME)
 
 
CASTOR, NCT02136134 / 2014-000255-85: Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Checkmark 4-year update of efficacy and safety data from CASTOR trial for multiple myeloma at ASH 2019
Dec 2019 - Dec 2019: 4-year update of efficacy and safety data from CASTOR trial for multiple myeloma at ASH 2019
Checkmark From CASTOR for RRMM at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: From CASTOR for RRMM at ASH 2018 [screenshot]
Checkmark From CASTOR for RRMM at ASH 2017 [screenshot]
More
Completed
3
498
Europe, US, RoW
Daratumumab, VELCADE (Bortezomib), VELCADE, Dexamethasone
Janssen Research & Development, LLC
Multiple Myeloma
01/16
01/24
POLLUX, NCT02076009 / 2013-005525-23: A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Checkmark Four-year follow up data from trial for multiple myeloma at ASH 2019
Dec 2019 - Dec 2019: Four-year follow up data from trial for multiple myeloma at ASH 2019
Checkmark Update from POLLUX trial for r/r multiple myeloma at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: Update from POLLUX trial for r/r multiple myeloma at ASH 2018 [screenshot]
Checkmark Update from POLLUX trial for r/r multiple myeloma at ASH 2018
More
Active, not recruiting
3
569
Europe, Canada, Japan, US, RoW
Daratumumab, Lenalidomide, Dexamethasone
Janssen Research & Development, LLC
Multiple Myeloma
03/16
08/24
NCT01685814 / 2009-016616-21: Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Active, not recruiting
3
406
Europe
Lenalidomide, Bortezomib, autologous stem cell transplant, allogeneic stem cell transplant
Wuerzburg University Hospital, ClinAssess GmbH, Celgene Corporation
Previously Untreated Symptomatic Multiple Myeloma
09/16
12/23
2015-002380-42: Research study to determine whether a combination of 3 drugs calledlenalidomide, carfilzomib and dexamethasone given to persons afterautologous stem cell (a young cell without a specific purpose from whichother cell types develop) transplant is better than lenalidomidemaintenance alone. Badanie Kliniczne prowadzone celem ustalenia czy kombinacja trzechleków o nazwie lenalidomid, carfilzomib i dexametazon podana osobom poautologicznej transplantacji komórek macierzystych (pierwotne,niewyspecjalizowane komórki nie posiadające określonego przeznaczenia,które mają zdolność do przekształcania się w wyspecjalizowane komórki)jest skuteczniejsza niż podawanie samego leku lenalidomid.

Ongoing
3
180
Europe
Dexamethasone, Capsule, hard, Powder for solution for infusion, Tablet, Revlimid, Kyprolis
Polish Myeloma Consortium, University of Chicago, Celgene Europe Ltd
Multiple Myeloma Szpiczak Mnogi, Cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies. Nowotwór, który powstaje z komórek plazmatycznych (produkujących przeciwciała)., Diseases [C] - Cancer [C04]
 
 
MAIA, NCT02252172 / 2014-002273-11: Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Checkmark Data from MAIA trial in combination with Revlimid for multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Data from MAIA trial in combination with Revlimid for multiple myeloma at ASH 2022
Checkmark From MAIA trial in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma at EHA 2021
Jun 2021 - Jun 2021: From MAIA trial in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma at EHA 2021
Checkmark Data from trial in combination with Revlimid for multiple myeloma at ASH 2020
More
Active, not recruiting
3
737
Europe, Canada, US, RoW
Daratumumab IV, JNJ-54767414, Lenalidomide, Dexamethasone, Daratumumab SC
Janssen Research & Development, LLC
Multiple Myeloma
09/18
09/24
ICARIA, NCT02990338 / 2016-003097-41: Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients

Checkmark From first part of ICARIA-MM trial for r/r multiple myeloma
Jun 2019 - Jun 2019: From first part of ICARIA-MM trial for r/r multiple myeloma
Checkmark Data from ICARIA-MM trial in r/r multiple myeloma
Feb 2019 - Feb 2019: Data from ICARIA-MM trial in r/r multiple myeloma
Completed
3
307
Europe, Canada, Japan, US, RoW
Isatuximab, SAR650984, Sarclisa, Pomalidomide, POMALYST IMNOVID, Dexamethasone
Sanofi
Plasma Cell Myeloma
11/18
11/23
2018-003535-30: IFM 2017-03 IFM 2017-03

Not yet recruiting
3
294
Europe
Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20), JnJ-54767414, Solution for injection, Capsule, Pillules, REVLIMID 25 mg gélules, NEOFORDEX 40mg comprimés
CHRU de Lille, CHU de Lille, Janssen Pharmaceutica NV
A Phase III Study Comparing Lenalidomide and Daratumumab (R-Dara) vs Lenalidomide and Dexamethasone (Rd) in Frail Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy. Etude de phase III comparant le Lénalidomide et le Daratumumab en injection sous cutanée versus le Lénalidomide et la Dexaméthasone chez des sujets fragiles atteints de myélome multiple en traitement de première ligne et non éligibles à une chimiothérapie à forte dose., Multiple Myeloma Myélome multiple, Diseases [C] - Cancer [C04]
 
 
2018-002068-15: A RANDOMIZED TRIAL THAT COMPARE CARFILZOMIB - LENALIDOMIDE - DEXAMETHASONE versus LENALIDOMIDE - DEXAMETHASONE IN NEWLY DIAGNOSED MYELOMA PATIENTS NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) Studio randomizzato che confronta carfilzomib – lenalidomide - desametasone con lenalidomide – desametasone in pazienti affetti da mieloma multiplo di nuova diagnosi non candidabili al trapianto autologo di cellule staminali (ASCT)

Not yet recruiting
3
340
Europe
CARFILZOMIB, LENALIDOMIDE, DESAMETASONE, Powder for solution for infusion, Capsule, hard, Oral drops, REVLIMID 25 MG, SOLDESAM
FO.NE.SA.Onlus, Celgene, Amgen
PATIENTS WITH NEW DIAGNOSIS MM WITH AGE ≥ 65 YEARS OR NOT ELIGIBLE TO ASCT PAZIENTI CON MM DI NUOVA DIAGNOSI CON ETÀ ≥ 65 ANNI O NON ELEGGIBILI AD ASCT, PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE ≥ 65 YEARS OR NOT ELIGIBLE TO ASCT PAZIENTI AFFETTI DA MIELOMA MULTIPLO DI NUOVA DIAGNOSI CON ETÀ ≥ 65 ANNI O NON ELEGGIBILI A TRAPIANTO, Diseases [C] - Cancer [C04]
 
 
LEPUS, NCT03234972: A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Completed
3
213
RoW
Daratumumab, Velcade, Dexamethasone
Janssen Research & Development, LLC
Multiple Myeloma
10/19
02/24
2018-004031-68: Research study to comparison the effectivenes of combination of drugs called lenalidomide, carfilzomib, dexamethasone with combination of drugs called lenalidomide, bortezomib, dexamethasone, given to patients with newly diagnosed multiple myeloma Badanie kliniczne prowadzone celem porównania skuteczności terapii kombinacją leków o nazwie lenalidomid, carfilzomib, deksametazon z kombinacją leków lenalidomid, bortezomib, deksametazon, podawanych pacjentom z nowo zdiagnozowanym szpiczakiem plazmocytowym

Ongoing
3
150
Europe
Dexamethasone, Bortezomib, Capsule, hard, Powder and solvent for concentrate for solution for infusion, Tablet, Powder for solution for injection, Revlimid, Kyprolis, Pabi-Dexamethason, Velcade
Polish Myeloma Consortium, University of Chicago, Celgene Switzerland Holdings Sàrl
Multiple Myeloma Szpiczak plazmocytowy, Cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies Nowotwór, który powstaje z komórek plazmatycznych (produkujących przeciwciała), Diseases [C] - Cancer [C04]
 
 
DSM XIII, NCT01090089: Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma

Completed
3
348
Europe
Lenalidomide, Dexamethasone, Revlimid, Lenalidomide, Dexamethasone, PBSCT
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH, ClinAssess GmbH
Multiple Myeloma
01/20
01/20
BOSTON, NCT03110562 / 2016-003957-14: Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

Checkmark From BOSTON trial for multiple myeloma
Jun 2021 - Jun 2021: From BOSTON trial for multiple myeloma
Checkmark Subgroup analysis data from BOSTON trial for r/r multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Subgroup analysis data from BOSTON trial for r/r multiple myeloma at ASH 2020
Checkmark Subgroup analysis data from BOSTON trial for r/r multiple myeloma at ASH 2020
More
Active, not recruiting
3
402
Europe, Canada, US, RoW
Selinexor, Bortezomib, Velcade®, Dexamethasone
Karyopharm Therapeutics Inc
Multiple Myeloma
02/20
09/23
The APOLLO Study, NCT03180736 / 2017-001618-27: Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone

Checkmark From trial in combination with pomalidomide/dexamethasone for multiple myeloma
Jul 2020 - Jul 2020: From trial in combination with pomalidomide/dexamethasone for multiple myeloma
Active, not recruiting
3
304
Europe, RoW
Daratumumab, Pomalidomide, Dexamethasone
European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
07/20
06/22
2020-000111-69: PACIFICA Phase 3: A Study of Pacritinib Versus Physician’s Choice in Patients with Myelofibrosis

Ongoing
3
348
Europe, RoW
Pacritinib, Ruxolitinib, Hydroxyurea, methylprednisolone, Dexamethasone, Prednisone, Capsule, hard, Tablet, Soluble tablet
CTI BioPharma Corp., CTI BioPharma Corp.
Primary Myelofibrosis, Post-essential thrombocythemia myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL), Post polycythaemia vera myelofibrosis, Primary or Secondary Myelofibrosis (MF), Diseases [C] - Cardiovascular Diseases [C14]
 
 
Cassiopeia, NCT02541383 / 2014-004781-15: A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

Checkmark Data from second part of CASSIOPEIA study in multiple myeloma
Oct 2020 - Oct 2020: Data from second part of CASSIOPEIA study in multiple myeloma
Checkmark From CASSIOPEIA trial at ASCO 2019
Jun 2019 - Jun 2019: From CASSIOPEIA trial at ASCO 2019
Checkmark From CASSIOPEIA trial multiple myeloma at EHA 2019
More
Active, not recruiting
3
1085
Europe
Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD), Arm A Part 1, Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab, Arm B Part 1, Daratumumab, Arm B Part 2
Intergroupe Francophone du Myelome, HOVON - Dutch Haemato-Oncology Association, Janssen Research & Development, LLC
Multiple Myeloma
08/20
06/23
2020-005883-78: Comparison of Prednisolone and Dexamethasone on D28 mortality in patients on oxygen therapy with CoViD-19 Comparaison de la Prednisolone et de la Dexaméthasone sur la mortalité à J28 chez des patients sous oxygénothérapie, atteints de la CoViD-19

Not yet recruiting
3
220
Europe
Solupred, Dectancyl, Orodispersible tablet, Prednisolone, Dexamethasone
Hospital Center rené Dubos, Hospital Center René Dubos
Care of severe forms of CoViD-19 from the transitional phase and the onset of the inflammatory phase with corticosteroids Prise en charge des formes sévères de CoViD-19 depuis la phase transitionnelle et le début de la phase inflammatoire par corticoïdes, Dexamethasone Prise en charge des formes sévères de CoViD-19 depuis la phase transitionnelle et le début de la phase inflammatoire par corticoïdes, Diseases [C] - Virus Diseases [C02]
 
 
2021-001242-35: A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Stem Cell Transplant is Not Planned as Initial Therapy

Ongoing
3
650
Europe, RoW
Bortezomib, Lenalidomide, Dexamethasone, Ciltacabtagene Autoleucel, JNJ-68284528, Powder for solution for injection, Capsule, hard, Tablet, Dispersion for infusion, VELCADE, Revlimid, Dexamethasone
Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development, LLC, Janssen Cilag SpA
Multiple Myeloma, Newly diagnosed multiple myeloma, Diseases [C] - Cancer [C04]
 
 
2020-004742-11: A randomized phase 3 study of Teclistamab in combination with daratumumab verses an Investigators choice of Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Velcade, Dexamethasone in Relapsed or Refractory Multiple Myeloma

Ongoing
3
560
Europe
Teclistamab, Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20), Imnovid, Dexamethasone, Velcade, JNJ-64007957, JNJ-54767414, Solution for injection, Capsule, Powder for solution for injection, Darzalex, Imnovid, Neofordex, Velcade
Janssen-Cilag International NV, Janssen Research & Development, LLC
Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
IKEMA, NCT03275285 / 2017-001940-37: Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

Checkmark PFS data from IKEMA trial in combination with carfilzomib and dexamethasone for 2L multiple myeloma
May 2022 - May 2022: PFS data from IKEMA trial in combination with carfilzomib and dexamethasone for 2L multiple myeloma
Checkmark Detailed data from P3 IKEMA trial in combination with carfilzomib and dexamethasone for r/r multiple myeloma
Jun 2020 - Jun 2020: Detailed data from P3 IKEMA trial in combination with carfilzomib and dexamethasone for r/r multiple myeloma
Checkmark From IKEMA trial in combination with carfilzomib and dexamethasone at ASCO 2020
More
Active, not recruiting
3
302
Europe, Canada, Japan, US, RoW
isatuximab SAR650984, Sarclisa, carfilzomib, Kyprolis, dexamethasone
Sanofi
Plasma Cell Myeloma
01/22
11/24
2020-006054-43: Randomized controlled trial to evaluate the efficacy of per-protocol administration of Methylprednisolone compared to Dexamethasone in SARS-CoV-2 infections requiring respiratory support. Studio randomizzato controllato per valutare l’efficacia della somministrazione secondo protocollo di Metilprednisolone rispetto a Desametasone nelle infezioni da SARS-CoV-2 necessitanti supporto respiratorio.

Not yet recruiting
3
680
Europe
Metilprednisolone, Desametasone, [MP], [DM], Solution for infusion
Università degli Studi di Trieste, Azienda Sanitaria Universitaria Giuliano-Isontina, Università degli Studi di Trieste
Hospitalized patients with COVID-19 requiring respiratory support Pazienti ospedalizzati con COVID-19 accertato con necessità di supporto respiratorio, COVID-19 COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Active, not recruiting
3
85
RoW
Pomalidomide, Dexamethasone
Qilu Pharmaceutical Co., Ltd.
Multiple Myeloma, Recurrent or Refractory
06/22
12/23
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
2021-004130-11: Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D for NDMM patients who are candidates for ASCT VRD extendido más rescate temprano vs. Isatuximab-VRD vs. Isatuximab-V-Iberdomida-D en MMND candidato a TASPE

Not yet recruiting
3
480
Europe
Iberdomide, ISATUXIMAB, LENALIDOMIDA, BORTEZOMIB, DEXAMETHASONE, CC-220, Capsule, soft, Concentrate for solution for infusion, Capsule, hard, Powder for solution for injection, Tablet, SARCLISA, REVLIMID, BORTEZOMIB TEVA, DEXAMETASONA TAD
FUNDACION PETHEMA, FUNDACION PETHEMA
Newly-diagnosed multiple myeloma (NDMM) patients who are candidates for Autologous Stem Cell Transplant (ASCT). Mieloma múltiple de nuevo diagnóstico (MMND) candidatos a trasplante autólogo de células madre hematopoyéticas (TASPE)., Newly-diagnosed multiple myeloma (NDMM) Mieloma múltiple de nuevo diagnóstico (MMND), Diseases [C] - Cancer [C04]
 
 
2022-000909-28: A randomized phase 3 study of Teclistamab in combination withdaratumumab and lenalidomide versus a combination of daratumumab, lenalidomide and dexamethasone in new multiple myeloma patients who cannot undergo stem cell transplant as the first therapy.

Ongoing
3
1030
Europe
Teclistamab, Daratumumab, Lenalidomide Accord, JNJ-64007957, JNJ-54767414, Solution for injection, Capsule, Darzalex, Lenalidomide Accord
Janssen-Cilag International NV, Janssen Research & Development, LLC
Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
DREAMM-3, NCT04162210 / 2018-004252-38: Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Checkmark Data from DREAMM-3 trial for 3L multiple myeloma
Nov 2022 - Nov 2022: Data from DREAMM-3 trial for 3L multiple myeloma
Hourglass Jul 2019 - Dec 2019 : Initiation of DREAMM-3 trial in r/r multiple myeloma
Active, not recruiting
3
325
Europe, Canada, Japan, US, RoW
Belantamab mafodotin, Pom/dex (Pomalidomide plus low dose Dexamethasone)
GlaxoSmithKline
Multiple Myeloma
09/22
06/25
2021-000202-22: A Randomized Study Comparing Talquetamab in Combination WithDaratumumab and Pomalidomide or Talquetamab in Combination WithDaratumumab Versus Daratumumab, Pomalidomide and Dexamethasone, in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

Ongoing
3
810
Europe, RoW
Talquetamab, Daratumumab, IMNOVID, Dexamethasone, JNJ-64407564, JNJ-54767414, Solution for injection, Capsule, hard, Tablet, Darzalex, IMNOVID, Dexamethasone JENAPHARM, Dexamethasone
Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development, LLC
Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
2021-001957-30: A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide in combination with bortezomib and dexamethasone in people who have Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment. Estudio para determinar la seguridad y eficacia de CC-92480 en combinación con bortezomib y dexametasona en comparación con pomalidamida, bortezomib y dexametasona en pacientes que tienen mieloma múltiple que no responde tras tratamiento o que reaparecido tras un tratamiento

Not yet recruiting
3
950
Europe
CC-92480, Bortezomib, Dexamethasone, Pomalidomide/Imnovid, [.], Capsule, hard, Solution for injection, Tablet, VELCADE, Dexamethasone Aspen, Dexamethasone-ratiopharm, Imnovid, Dexamethason-JENAPHARM®, Dexamethason-Galen
Celgene Corporation, CELGENE CORPORATION, Celgene Corporation
Relapsed or Refractory Multiple Myeloma (RRMM) Mieloma Múltiple en recaída o refractario, Relapsed or Refractory Multiple Myeloma (RRMM) Mieloma Múltiple en recaída o refractario, Diseases [C] - Cancer [C04]
 
 
2021-000803-20: MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Lenalidomide + Dexamethasone in Transplant-Ineligible Participants With Newly-Diagnosed Multiple Myeloma

Ongoing
3
646
Europe
Elranatamab, Daratumumab, Lenalidomide 5 mg, Dexamethasone 20 mg, Lenalidomide 10 mg, Lenalidomide 15 mg, Lenalidomide 20 mg, Lenalidomide 25 mg, Dexamethasone 4 mg, PF-06863135, Solution for injection, Capsule, Tablet, DARZALEX 1800 mg solution for injection
Pfizer Inc., Pfizer, Inc.
Multiple myeloma, Hematological malignancy, Diseases [C] - Cancer [C04]
 
 
NCT04287660: Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

Recruiting
3
20
RoW
clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells
The First Affiliated Hospital of Soochow University, Changshu Frist People's Hospital, Huai'an Second People's Hospital, Affiliated Hospital of Jiangnan University, Jiangsu Province Hospital of Traditional Chinese Medicine, Jiangyin People's Hospital, Jingjiang People's Hospital, The Third People's Hospital of Kunshan, Lianyungang Hospital Affiliated Bengbu Medical College, Suzhou Municipal Hospital, Zhangjiagang First People's Hospital, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital with Nanjing Medical University, The first Affiliated Hospital of Nanjing University Medical School
Multiple Myeloma
01/23
01/25
2022-000996-38: Trial in patients with newly diagnosed myeloma to assess non-inferiority of induction therapy with isatuximab/lenalidomide/ bortezomib/ dexamethasone when isatuximab is administered subcutaneously versus intravenously Studie für Patienten mit zuvor unbehandeltem Multiplen Myelom zur Untersuchung der Wirksamkeit der Induktionstherapie mit Isatuximab/Lenalidomid/ Bortezomib/ Dexamethason bei Gabe von Isatuximab unter die Haut (subkutan) gegenüber einer Gabe in die Vene (intravenös) als Vergleichsmethode

Ongoing
3
514
Europe
Isatuximab, SAR650984, Concentrate for solution for infusion, Solution for injection
Ruprecht-Karls-Universität Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg, Sanofi-Aventis Recherche & Developpement
Newly diagnosed symptomatic multiple myeloma Symptomatisches Multiples Myelom, Primärtherapie, Symptomatic, newly diagnosed (previously untreated) multiple myeloma Bisher unbehandeltes, symptomatisches Multiples Myelom, Diseases [C] - Cancer [C04]
 
 
EARLYDEXCoV2, NCT04836780: DEXamethasone EARLY Administration in Hospitalized Patients With Covid-19 Pneumonia

Recruiting
3
126
Europe
Dexamethasone, Dexametasona kern pharma solution for injection 4 mg/ml
Hospital Universitario Infanta Leonor, Fundación para la Investigación e Innovación Biomédica del Hospital Universitario Infanta Leonor, Kern Pharma, S.L.
COVID-19, Acute Respiratory Distress Syndrome, Pneumonia, Viral
02/23
03/23
Neptuno, NCT04784559 / 2020-005951-19: Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

Terminated
3
205
Europe, RoW
Plitidepsin, Dexamethasone, Remdesivir, Favipiravir
PharmaMar
COVID-19 Infection
03/23
03/23
ARROW2, NCT03859427 / 2018-000665-36: A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Completed
3
454
Europe, Japan, US, RoW
Carfilzomib, Lenalidomide, Dexamethasone
Amgen
Relapsed or Refractory Multiple Myeloma
03/23
03/23
DREAMM 7, NCT04246047 / 2018-003993-29: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Calendar Jan 2024 - Dec 2024: Market entry for 2L multiple myeloma (based on DREAMM-7 trial)
Jul 2023 - Dec 2023: Acceptance of regulatory submission in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jul 2023 - Dec 2023: Acceptance of regulatory submissions in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jul 2023 - Dec 2023: Data readout from DREAMM-7 trial for 2L+ multiple myeloma
Jul 2023 - Dec 2023: Acceptance of regulatory submission in US for 2L+ multiple myeloma (based on DREAMM-8 trial)
More
Active, not recruiting
3
571
Europe, Canada, Japan, US, RoW
Belantamab mafodotin, Daratumumab, Bortezomib, Dexamethasone
GlaxoSmithKline
Multiple Myeloma
10/23
06/26
NCT04654507: Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children

Recruiting
3
120
RoW
Dexamethasone Oral, corticosteroids, Placebo
Hamad Medical Corporation
Urinary Tract Infections in Children, Dexamethasone, Kidney Scarring, Acute Pyelonephritis, Hypertension in Children, Chronic Renal Failure, UTI
12/23
12/24
MK-5684-004, NCT06136650: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA

Recruiting
3
1500
Europe, Japan, US, RoW
Opevesostat, MK-5684, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate, Zytiga, Yonsa, Prednisone acetate, Enzalutamide, Xtandi
Merck Sharp & Dohme LLC, Orion Corporation, Orion Pharma
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
12/30
12/30
MK-5684-003, NCT06136624: Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Opevesostat, MK-5684, Abiraterone acetate, ZYTIGA, YONSA, Enzalutamide, XTANDI, Hydrocortisone, Fludrocortisone acetate, Prednisone, Dexamethasone
Merck Sharp & Dohme LLC, Orion Corporation, Orion Pharma
Prostate Cancer Metastatic
08/28
08/28
MagnetisMM-32, NCT06152575: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Recruiting
3
492
Europe, Canada, Japan, US, RoW
Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib
Pfizer
Multiple Myeloma
12/25
03/28
CATCO, NCT04330690: Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Active, not recruiting
3
2900
Canada
Artesunate, Imatinib, Infliximab, Dexamethasone, LSALT Peptide
Sunnybrook Health Sciences Centre, AbbVie, Apotex Inc., World Health Organization, University of British Columbia, Arch Biopartners Inc.
COVID-19
03/24
05/24
FUMANBA-03, NCT06464991: A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM

Recruiting
3
240
RoW
Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone
Nanjing IASO Biotechnology Co., Ltd.
Multiple Myeloma
08/27
12/30
IFM2020-05, NCT04751877: Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

Active, not recruiting
3
270
Europe
Isatuximab, Lenalidomide, Bortezomib, Dexamethasone
Poitiers University Hospital, Intergroupe Francophone du Myelome, Sanofi
Multiple Myeloma, Myeloma
04/24
08/27
NCT06216158: Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

Recruiting
3
411
Europe
Iberdomide, Isatuximab, Sarclisa, Dexamethasone
University of Heidelberg Medical Center, KKS Netzwerk, Wuerzburg University Hospital, Sanofi, Bristol-Myers Squibb
Multiple Myeloma
12/28
06/29
ALUMMINATE, NCT06232707: A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Withdrawn
3
466
Europe, Canada, Japan, US, RoW
Alnuctamab, BMS-986349, CC-93269, Pomalidomide, POMALYST®, IMNOVID®, CC-4047, BMS-986379, Daratumumab, DARZALEX®, DARZALEX, FASPRO®, Elotuzumab, Empliciti®, BMS-901608, Carfilzomib, KYPROLIS®, Dexamethasone
Celgene
Multiple Myeloma
11/25
09/30
NCT06158841: Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
3
380
Europe, RoW
ABBV-383, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone
AbbVie
Multiple Myeloma
12/27
01/28
NCT05405166 / 2021-002485-41: SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

Active, not recruiting
3
534
Europe, Canada, Japan, US, RoW
Isatuximab IV, SAR650984, SARCLISA®, Isatuximab SC, Dexamethasone, Pomalidomide, Pomalyst or equivalent, Montelukast, Paracetamol / Acetaminophen, Diphenhydramine, Methylprednisolone
Sanofi, Sanofi-aventis recherche & developpement
Plasma Cell Myeloma Recurrent
11/24
03/27
NCT03952091: TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Checkmark Initiation of pivotal trial in multiple myeloma
May 2019 - May 2019: Initiation of pivotal trial in multiple myeloma
Completed
3
289
RoW
TJ202, Lenalidomide and Dexamethasone, Lenalidomide and Dexamethasone
TJ Biopharma Co., Ltd.
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
06/24
06/24
MK-2870-009, NCT06305754: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

Recruiting
3
520
US, RoW
Sacituzumab tirumotecan, SKB264, MK-2870, Pemetrexed, Carboplatin, Antihistamine, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent)
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
09/28
06/30
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Active, not recruiting
3
150
RoW
SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone)
Antengene Corporation
Relapsed or Refractory Multiple Myeloma
07/24
10/24
TT4B, NCT00734877: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

Active, not recruiting
3
382
US
M-VTD-PACE, Melphalan, Velcade, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide, TT3-LITE Regimen (L-TT3), Velcade (bortezomib)
University of Arkansas, Millennium Pharmaceuticals, Inc.
Multiple Myeloma
09/25
09/26
NCT02516423: Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

Active, not recruiting
3
11
US
ixazomib, lenalidomide, dexamethasone, zoledronic acid
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Millennium Pharmaceuticals, Inc., Biologics, Inc.
Solitary Osseous Plasmacytoma
09/24
 
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Calendar Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
Calendar Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jul 2023 - Dec 2023: Data readout from DREAMM-8 trial in combination with pomalidomide and dexamethasone for 2L+ multiple myeloma
Jul 2023 - Dec 2023: Acceptance of regulatory submission in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jul 2023 - Dec 2023: Acceptance of regulatory submissions in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
More
Recruiting
3
357
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
05/29
GEM-CLARIDEX, NCT02575144 / 2015-001183-19: Ld vs BiRd

Active, not recruiting
3
286
Europe
Clarithromycin, Lenalidomide, Dexamethasone
PETHEMA Foundation, Cabyc, S.L.
Multiple Myeloma
10/24
10/24
iMMagine-3, NCT06413498: A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Not yet recruiting
3
450
NA
Anitocabtagene Autoleucel, CART-ddBCMA, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib
Kite, A Gilead Company, Arcellx, Inc.
Multiple Myeloma
07/28
07/31
ML43171, NCT05306340 / 2022-000199-20: A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Recruiting
3
320
Europe, Japan, US, RoW
Giredestrant, GDC-9545, RO7197597, RG6171, Exemestane, Fulvestrant, Tamoxifen, Everolimus, LHRH Agonist, Dexamethasone Mouth Rinse
Genentech, Inc.
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
10/24
03/26
FiTNEss, NCT03720041 / 2018-003590-10: Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
740
Europe
R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, Ninlaro, Revlimid, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance, R2: Lenalidomide + ixazomib maintenance
University of Leeds, Cancer Research UK, Takeda, Celgene
Multiple Myeloma
12/24
12/24
NCT04504825 / 2019-004254-28: A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

Active, not recruiting
3
124
Europe, Canada, Japan, US, RoW
CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
Alexion Pharmaceuticals, Inc.
AL Amyloidosis
12/24
12/26
MAGNETISMM-5, NCT05020236 / 2021-000044-22: MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Recruiting
3
761
Europe, Canada, Japan, US, RoW
Elranatamab, PF-06863135, Daratumumab, Darzalex Faspro; Darzalex solution for injection, Pomalidomide, Pomalyst, Imnovid, Dexamethasone
Pfizer
Multiple Myeloma
08/25
05/27
NCT04512235 / 2020-000713-32: A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis

Active, not recruiting
3
267
Europe, Canada, Japan, US, RoW
CAEL-101, Anselamimab, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
Alexion Pharmaceuticals, Inc.
AL Amyloidosis
03/25
03/27
Perseus, NCT03710603 / 2018-002992-16: Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

Hourglass Jan 2022 - Dec 2022 : From PERSEUS trial in combination with Darzalex for 1L multiple myeloma
Active, not recruiting
3
690
Europe, RoW
Daratumumab, velcade (bortezomib), lenalidomide, dexamethasone, velcade, bortezomib, Lenalidomide
European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
05/25
11/29
NCT05804032 / 2022-000996-38: Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
514
Europe
Isatuximab, Sarclisa, Lenalidomide, Bortezomib, Velcade, Dexamethasone
University of Heidelberg Medical Center, Deutsche Studiengruppe Multiples Myelom (DSMM), KKS Netzwerk, Sanofi
Multiple Myeloma
07/25
07/26
IsKia, NCT04483739 / 2019-004844-32: Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation ( TRIAL)

Active, not recruiting
3
302
Europe, RoW
Carfilzomib Lenalidomide Dexamethasone, KRd, Isatuximab Carfilzomib Lenalidomide Dexamethasone, Isa-KRD
European Myeloma Network, EMN Research Italy, Sanofi, Amgen
Multiple Myeloma
07/25
12/32
MajesTEC-3, NCT05083169 / 2020-004742-11: A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

Active, not recruiting
3
587
Europe, Canada, Japan, US, RoW
Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Teclistamab, JNJ-64007957
Janssen Research & Development, LLC, Janssen Research & Development, LLC
Multiple Myeloma
08/25
12/28
MajesTEC-9, NCT05572515: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
3
590
Europe, Canada, Japan, US, RoW
Teclistamab, JNJ-64007957, Pomalidomide, Bortezomib, Dexamethasone, Carfilzomib
Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma
10/25
08/31
NCT03652064 / 2018-001545-13: A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Hourglass Jan 2023 - Dec 2023 : Data from CEPHEUS trial for transplant ineligible frontline multiple myeloma
Active, not recruiting
3
395
Europe, Canada, Japan, US, RoW
Daratumumab, JNJ-54767414, DARZALEX, Bortezomib, Velcade, Lenalidomide, Revlimid, Dexamethasone
Janssen Research & Development, LLC
Multiple Myeloma
08/25
10/28
MonumenTAL-3, NCT05455320 / 2021-000202-22: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

Recruiting
3
810
Europe, Japan, US, RoW
Talquetamab, JNJ-64407564, Daratumumab, Pomalidomide, Dexamethasone
Janssen Research & Development, LLC, Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma
02/26
09/29
CANOVA, NCT03539744 / 2017-003838-88: A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Jan 2023 - Jun 2023: Data from CANOVA trial for r/r multiple myeloma
Active, not recruiting
3
265
Europe, Canada, Japan, US, RoW
Pomalidomide, Pomalyst, Dexamethasone, Venetoclax, ABT-199, GDC-0199
AbbVie, Roche-Genentech
Multiple Myeloma
08/26
08/26
ACCoRd, NCT03562169: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII

Recruiting
3
406
Europe
Ixazomib, thalidomide, & dexamethasone (ITD) re-induction, Conventional autologous stem cell transplant (ASCT-con), Augmented autologous stem cell transplant (ASCT-aug), ITD consolidation and ixazomib maintenance vs. No further therapy
University of Leeds, Cancer Research UK, Takeda
Multiple Myeloma
03/26
03/27
NCT05028348 / 2021-001691-41: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Calendar Jul 2024 - Dec 2024: Top-line data from XPORT-MM-031 trial in combination with pomalidomide and dexamethasone for multiple myeloma
Jun 2023 - Dec 2023: Completion of enrolment of trial in combination with pomalidomide and dexamethasone for multiple myeloma
Recruiting
3
222
Europe, US
Selinexor, KPT-330, Elotuzumab, Pomalidomide, Dexamethasone Oral
Stichting European Myeloma Network, Karyopharm Therapeutics Inc
Multiple Myeloma
03/26
03/29
EXCALIBER, NCT04975997 / 2020-000431-49: Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dexamethasone, Daratumumab, DARZALEX FASPRO, Bortezomib, Iberdomide, CC-220, BMS-986382
Celgene
Multiple Myeloma
03/26
06/32
IDRIS, NCT02544308 / 2015-001355-76: Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

Active, not recruiting
3
36
Europe
Lenalidomide, Revlimid, Dexamethasone, No further treatment
University College, London, Cancer Research UK, Celgene
Plasmacytoma
04/26
12/26
IMROZ, NCT03319667 / 2017-002238-21: Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant

Calendar Jan 2024 - Dec 2024: Submission for newly diagnosed multiple myeloma (based on IMROZ trial)
Hourglass Oct 2023 - Dec 2023 : Pivotal data readout from IMROZ trial for 1L multiple myeloma
Hourglass Oct 2021 - Mar 2022 : Regulatory submissions for NDMM (based on IMROZ trial) in EU
Hourglass Jan 2021 - Dec 2021 : Primary data from IMROZ trial for newly diagnosed multiple myeloma
Active, not recruiting
3
475
Europe, Japan, US, RoW
Isatuximab SAR650984, Sarclisa, Bortezomib, Velcade®, Lenalidomide, Dexamethasone
Sanofi
Plasma Cell Myeloma
04/26
06/27
CARTITUDE-4, NCT04181827 / 2019-001413-16: A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Hourglass Sep 2023 - Sep 2023 : Safety and efficacy data from CARTITUDE-4 trial in adults with relapsed and lenalidomide-refractory multiple myeloma
Hourglass Jun 2023 - Jun 2023 : Data from CARTITUDE-4 trial for relapsed/refractory multiple myeloma at EHA 2023
Checkmark Data from CARTITUDE-4 trial for relapsed/refractory multiple myeloma
Jan 2023 - Jan 2023: Data from CARTITUDE-4 trial for relapsed/refractory multiple myeloma
Active, not recruiting
3
419
Europe, Japan, US, RoW
JNJ-68284528, Cilta-cel, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab
Janssen Research & Development, LLC
Multiple Myeloma
05/24
06/27
CARTITUDE-5, NCT04923893 / 2021-001242-35: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

Recruiting
3
650
Europe, Canada, Japan, US, RoW
Bortezomib, Dexamethasone, Lenalidomide, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Janssen Research & Development, LLC, Janssen Research & Development, LLC, Janssen Cilag SpA
Multiple Myeloma
06/26
12/34
GEM21menos65, NCT05558319: NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

Not yet recruiting
3
480
Europe
Bortezomib, Isatuximab, Iberdomide, Lenalidomide, Dexamethasone
PETHEMA Foundation, Bristol-Myers Squibb, Sanofi, Adknoma, Start from scratch
Newly Diagnosed Multiple Myeloma
04/27
04/29
KarMMa-3, NCT03651128 / 2018-001023-38: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Hourglass Jun 2023 - Jun 2023 : Subgroup analysis of outcomes for patients with high-risk r/r multiple myeloma from the KarMMa-3 trial at EHA 2023
Checkmark Data from KarMMa-3 trial for 3L multiple myeloma
Aug 2022 - Aug 2022: Data from KarMMa-3 trial for 3L multiple myeloma
Active, not recruiting
3
381
Europe, Canada, Japan, US
bb2121, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Ixazomib, Lenalidomide, Carfilzomib, Elotuzumab
Celgene
Multiple Myeloma
04/27
04/27
MagnetisMM-6, NCT05623020 / 2021-000803-20: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Recruiting
3
966
Europe, Canada, Japan, RoW
Elranatamab, Daratumumab, Lenalidomide, Dexamethasone
Pfizer, Pfizer, Inc.
Multiple Myeloma
03/28
11/31
ITHACA, NCT04270409 / 2019-003139-47: A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma

Active, not recruiting
3
337
Europe, Canada, Japan, US, RoW
Isatuximab SAR650984, Sarclisa, Lenalidomide, Dexamethasone, Montelukast or equivalent, Acetaminophen, Diphenhydramine or equivalent, Methylprednisolone or equivalent
Sanofi
Plasma Cell Myeloma
11/30
10/33
MajesTEC-7, NCT05552222 / 2022-000909-28: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
1590
Europe, Canada, Japan, RoW
Teclistamab, JNJ-64007957, Daratumumab, Lenalidomide, Dexamethasone, Talquetamab, JNJ-64407564
Janssen Research & Development, LLC, Janssen Research & Development, LLC
Multiple Myeloma
04/31
10/33
DSMM XVII, NCT03948035 / 2017-001616-11: Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

Active, not recruiting
3
576
Europe
Elotuzumab, Empliciti®, Carfilzomib, Kyprolis®, Lenalidomide, Revlimid®, Dexamethasone, Fortecortin®, autologous stem cell transplant
Wuerzburg University Hospital, ClinAssess GmbH, Arbeitsgemeinschaft medikamentoese Tumortherapie
Newly Diagnosed Multiple Myeloma
08/29
08/29
CARTITUDE-6, NCT05257083: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Stichting European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
06/33
08/40
2010-021445-42: A study in which is investigated if the medicine bortezomib is effective in patients with AL amyloidosis

Ongoing
2/3
50
Europe
Fortecortin, Powder for solution for injection, Velcade
HOVON Foundation, Dutch Cancer Society, Janssens Pharma NV
AL Amyloidosis, AL amyloidosis, Diseases [C] - Cancer [C04]
 
 
2010-021091-28: A clinical study to determine whether a new drug masitinib is safe and effective in cancer of the white blood cells.

Ongoing
2/3
267
Europe, RoW
Masitinib mesylate, Gemcitabine, Dexamethasone, AB1010, Film-coated tablet, Powder for infusion, Tablet, Gemcitabine, Dexamethasone
AB Science, AB Science
Relapsed or refractory peripheral T-cell lymphoma, Cancer of the white blood cells (T-lymphocytes), Diseases [C] - Cancer [C04]
 
 
NCT03668639: Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin

Recruiting
2/3
80
Europe
Akynzeo, Dexamethasone
Christina Ruhlmann, Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting, Adverse Event, Cervical Cancer
03/23
04/23
NATADEX, NCT04452565: NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

Recruiting
2/3
525
US
Drug: NA-831, NA-831 and Atazanavir, and Atazanavir, NA-831and Dexamethasone, Dexamethasone, Atazanavir and Dexamethasone
NeuroActiva, Inc., Biomed Industries, Inc.
Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
12/23
12/23
NCT05546359: Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients

Recruiting
2/3
410
Europe, Canada, US
Amisulpride Injection, Barhemsys, Dexamethasone, Decadron
Acacia Pharma Ltd, Amicus CD LLC, Premier Research Group plc
Nausea and Vomiting, Postoperative
06/25
12/25
NCT06212336: ISTH/ANRS 0409s INTEGRATE Lassa Fever Study

Not yet recruiting
2/3
1755
NA
Favipiravir, Ribavirin, Standard of care, Dexamethasone
Irrua Specialist Teaching Hospital, Alliance for International Medical Action, University of Bordeaux, Bernhard Nocht Institute for Tropical Medicine, Federal Medical Centre, Owo, Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire, Fondation pour la Recherche Scientifique, Benin, Médecins Sans Frontières, Belgium, Alex Ekwueme Federal University Teaching Hospital, Donka Hospital, Conakry, Centre de Recherche Médicale de Lambaréné, University of Hamburg-Eppendorf, Phebe Hospital, Liberia, University of North Carolina, ANRS, Emerging Infectious Diseases
Lassa Fever
06/27
06/27
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/Refractory Diffuse Large B-cell Lymphoma
12/24
12/25
Glo-BNHL, NCT05991388: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Not yet recruiting
2/3
210
NA
Odronextamab, REGN-1979, Loncastuximab tesirine, ADCT-402, Rituximab, Ifosfamide, Carboplatin, Etoposide, Etoposide Phosphate, Dexamethasone, CAR T-cells (TBC)
University of Birmingham, Cancer Research UK, Fight Kids Cancer, Regeneron Pharmaceuticals, ADC Therapeutics SA
B-cell Non Hodgkin Lymphoma
05/31
05/33

Download Options